Royce & Associates’s Cytosorbents Corp CTSO Stock Holding History

Royce & Associates’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-349,000	Closed	-$764K	–	943
2022 Q2	$764K	Hold	349,000	–	–	0.01%	790
2022 Q1	$1.11M	Buy	349,000 +98,000	+39%	+$351K	0.01%	800
2021 Q4	$1.05M	Buy	251,000 +55,000	+28%	+$309K	0.01%	799
2021 Q3	$1.59M	Buy	196,000 +59,000	+43%	+$479K	0.01%	766
2021 Q2	$1.03M	Hold	137,000	–	–	0.01%	847
2021 Q1	$1.19M	Hold	137,000	–	–	0.01%	833
2020 Q4	$1.09M	Hold	137,000	–	–	0.01%	804
2020 Q3	$1.09M	Buy	137,000 +20,000	+17%	+$180K	0.01%	770
2020 Q2	$1.16M	Buy	117,000 +53,688	+85%	+$493K	0.01%	755
2020 Q1	$489K	Buy	+63,312	New	+$320K	0.01%	836

Other funds holding CTSO

Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Royce & Associates's CTSO Position: Q3 2022 in Review

Royce & Associates sold out of Cytosorbents Corp (CTSO) in Q3 2022, closing a stake of 349,000 shares — an estimated $764K sold.

Royce & Associates first reported a position in CTSO in Q1 2020 and held it in 10 quarters. The position peaked at $1.59M in Q3 2021. 60 funds tracked by Wall St. Rank hold CTSO as of Q3 2022.

Royce & Associates reported no remaining Cytosorbents Corp position as of Q3 2022 after selling out during the quarter.
Royce & Associates sold 349,000 Cytosorbents Corp shares in Q3 2022, an estimated $764K.
Royce & Associates first reported a position in Cytosorbents Corp in Q1 2020 and held it in 10 quarters.
Royce & Associates's Cytosorbents Corp position peaked at $1.59M in Q3 2021.
60 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2022.

Based on Royce & Associates's 13F filing for Q3 2022, filed 3 Nov 2022.